

ANDA 75-185

Food and Drug Administration Rockville MD 20857

NOV 1 3 1998

Carlsbad Technology, Inc. Attention: Bruce J. C. Liu 5923 Balfour Court

Carlsbad, CA

Dear Sir:

This is in reference to your abbreviated new drug application dated August 11, 1997, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act, for Diclofenac Sodium Delayed-release Tablets USP, 25, 50, and 75 mg.

Reference is also made to your amendments dated January 15, January 29, April 29, July 22, August 7, August 19, and October 5, and October 28, 1998.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Diclofenac Sodium Delayed-release Tablets USP, 25, 50, and 75 mg, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Voltaren Delayedrelease Tablets, 25, 50, and 75 mg, respectively, of Ciba Vision Corp). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under 21 CFR 314.70, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print.

Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-40). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FD-2253 at the time of their initial use.

Sincerely yours,

Douglas L. Sporn

Director

Office of Generic Drugs

Center for Drug Evaluation and Research